[Metformin associated with lactic acidosis in treatment of type 2 diabetes].
Metformin (MET) is the first-line agent in treatment of type 2 diabetes. However, MET has been associated with lactic acidosis (MALA), a potential but rare complication which has influenced treatment strategies in decades. Recently, guidelines have been changed in regards of age and heart failure and the contradiction of chronic renal impairment has been debated. This article identifies potential risk groups and situations that would benefit from a temporary interruption in the MET treatment.
Klinisk Farmakologisk Afdeling, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 København NV, Denmark.
Helle
H
Holst
Ebbe
E
Eldrup
Nana Harriet
NH
Guldstad
Hans Henrik
HH
Bülow
Hanne Rolighed
HR
Christensen
D000140:Acidosis, Lactic / Q000139:chemically induced* / Q000453:epidemiology; D000368:Aged; D000369:Aged, 80 and over; D000075202:Contraindications; D003718:Denmark; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors
D007004:Hypoglycemic Agents; D008687:Metformin